The Asia Pacific Body Fluid Collection And Diagnostics Market would witness market growth of 7.4% CAGR during the forecast period (2022-2028).
The examination of body fluid performs a crucial role in the diagnosis and prognosis of a disease. A physiological or pathological condition is indicated by a change in the concentration or content of a certain biochemical ingredient in body fluids. A specific component in human body fluids can be observed as a marker for the identification of a disease.
Detection of these types of markers in an early phase can cause a rise in diagnosis, which can allow the start of necessary therapeutic treatment. The tracking of a specific chemical species throughout the course of disease among the endogenous or exogenous compounds can further provide details regarding the effectiveness of a specific therapy.
The number of people participating in the basic old-age insurance scheme across China had reached 175 million, out of which 43.67 million were retirees, by the end of 2005. The total spending of the old-age insurance fund was 404 billion yuan. The state has also set up an adjustment mechanism for the basic pension by which the state adjusts the level of the basic pension of enterprise retirees in light of price fluctuations & wage raises of enterprise employees. The high old age funds and the rising geriatric population will propel the healthcare spending from this age group. Thus, with the rising number of old aged population, the market for body fluid collection and diagnostics market in the Asia Pacific region.
The China market dominated the Asia Pacific Body Fluid Collection And Diagnostics Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $2,861.8 million by 2028. The Japan market is estimated to grow a CAGR of 6.8% during (2022 - 2028). Additionally, The India market would experience a CAGR of 8.1% during (2022 - 2028).
Based on Product, the market is segmented into Kits & Consumables, Instruments and Tests/Services. Based on Technology, the market is segmented into Polymerase Chain Reaction (PCR), Next Generation Sequencing (NGS), Fluorescence in situ hybridization (FISH) and Others. Based on Sample Type, the market is segmented into Blood, Urine, Saliva and Cerebrospinal Fluid. Based on Application, the market is segmented into Diagnostics & Monitoring, Therapeutic Decision Making and Prognostics & Screening. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
Free Valuable Insights: The Worldwide Body Fluid Collection And Diagnostics Market is Projected to reach USD 42.2 Billion by 2028, at a CAGR of 6.9%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Thermo Fisher Scientific, Inc., Bio-Rad Laboratories, Inc., Illumina, Inc., Qiagen N.V., Johnson & Johnson, F. Hoffmann-La Roche Ltd., Laboratory Corporation of America Holdings, Biocept, Inc., MDxHealth SA, and Guardant Health, Inc.
By Product
By Technology
By Sample Type
By Application
By Country
Unique Offerings Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
